Inhibition of Notch signaling by Dll4-Fc promotes reperfusion of acutely ischemic tissues

Biochemical and Biophysical Research Communications

Volumn 418, Issue 1, 2012, Pages 173-179

  Liu, Ren ^a   Trindade, Alexandre ^b,c   Sun, Zhanfeng ^d   Kumar, Ram ^e   Weaver, Fred A ^e   Krasnoperov, Valery ^f   Naga, Kranthi ^f   Duarte, Antonio ^b,c   Gill, Parkash S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b FACULDADE DE MEDICINA VETERINÁRIA   (Portugal)

^c INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^d THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f Vasgene Therapeutics   (United States)

Author keywords

Angiogenesis; Dll4 Fc; Dll4 Notch; Ischemia; Perfusion

Indexed keywords

ANGIOGENESIS INHIBITOR; DLL4 FUSION PROTEIN; NEUTRALIZING ANTIBODY; NOTCH RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; GRAFT SURVIVAL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIMB ISCHEMIA; MALE; MATURATION; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION; SIGNAL TRANSDUCTION; SKIN FLAP; TISSUE INJURY; TISSUE PERFUSION; VASCULARIZATION;

ANIMALS; BLOOD VESSELS; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE; FREE TISSUE FLAPS; HINDLIMB; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISCHEMIA; MEMBRANE PROTEINS; MICE; MICE, MUTANT STRAINS; RECEPTORS, NOTCH; RECOMBINANT FUSION PROTEINS; REPERFUSION; SIGNAL TRANSDUCTION; SKIN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84863403912     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.01.002     Document Type: Article

References (17)

1. Gurtner G.C., Werner S., Barrandon Y., Longaker M.T. Wound repair and regeneration. Nature 2008, 453:314-321.
2. Werner S., Grose R. Regulation of wound healing by growth factors and cytokines. Physiol. Rev. 2003, 83:835-870.
3. Hsieh P.C., MacGillivray C., Gannon J., Cruz F.U., Lee R.T. Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation 2006, 114:637-644.
4. Balfour J.A., Noble S. Becaplermin. Bio Drugs 1999, 11:359-364.
5. Franz M.G., Steed D.L., Robson M.C. Optimizing healing of the acute wound by minimizing complications. Curr. Probl. Surg. 2007, 44:691-763.
6. Shutter J.R., Scully S., Fan W., Richards W.G., Kitajewski J., Deblandre G.A., Kintner C.R., Stark K.L. Dll4, a novel notch ligand expressed in arterial endothelium. Genes Dev. 2000, 14:1313-1318.
7. Duarte A., Hirashima M., Benedito R., Trindade A., Diniz P., Bekman E., Costa L., Henrique D., Rossant J. Dosage-sensitive requirement for mouse Dll4 in artery development. Genes Dev. 2004, 18:2474-2478.
8. Benedito R., Duarte A. Expression of Dll4 during mouse embryogenesis suggests multiple developmental roles. Gene Expr. Patterns 2005, 5:750-755.
9. Scehnet J.S., Jiang W., Kumar S.R., Krasnoperov V., Trindade A., Benedito R., Djokovic D., Borges C., Ley E.J., Duarte A., Gill P.S. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 2007, 109:4753-4760.
10. Noguera-Troise I., Daly C., Papadopoulos N.J., Coetzee S., Boland P., Gale N.W., Lin H.C., Yancopoulos G.D., Thurston G. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006, 444:1032-1037.
11. Ridgway J., Zhang G., Wu Y., Stawicki S., Liang W.C., Chanthery Y., Kowalski J., Watts R.J., Callahan C., Kasman I., Singh M., Chien M., Tan C., Hongo J.A., de Sauvage F., Plowman G., Yan M. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006, 444:1083-1087.
12. Trindade A., Kumar S.R., Scehnet J.S., Lopes-da-Costa L., Becker J., Jiang W., Liu R., Gill P.S., Duarte A. Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos. Blood 2008, 112:1720-1729.
13. Williams C.K., Li J.L., Murga M., Harris A.L., Tosato G. Up-regulation of the notch ligand delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 2006, 107:931-939.
14. Thurston G., Noguera-Troise I., Yancopoulos G.D. The delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat. Rev. Cancer 2007, 7:327-331.
15. Clayton J.A., Chalothorn D., Faber J.E. Vascular endothelial growth factor-A specifies formation of native collaterals and regulates collateral growth in ischemia. Circ. Res. 2008, 103:1027-1036.
16. Djokovic D., Trindade A., Gigante J., Badenes M., Silva L., Liu R., Li X., Gong M., Krasnoperov V., Gill P.S., Duarte A. Combination of Dll4/Notch and ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis. BMC Cancer 2010, 10:641.
17. Lee D.J., Lyshchik A., Huamani J., Hallahan D.E., Fleischer A.C. Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model. J. Ultrasound Med. 2008, 27:855-866.